Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Allergan Plc (AGN) Explodes After FDA Approval Of Natrelle Inspira

Allergan Plc (NYSE:AGN) is trading higher in the market early into the New Year, after clinching FDA approval for its breast implant treatment, Natrelle Inspira. The approval goes a long way in providing women undergoing breast reconstruction or augmentation a new cohesive implant option.

Natrelle Inspira Approval

The FDA approval also makes Allergan SoftTouch breast implants the only implant line in the market with three levels of cohesive gel. What this means is that physicians can now meet diverse patient needs depending on breast tissue and desired outcomes according to Chief R&D officer David Nicholson.

Allergan Beauty Products Avon AGN ACT AVP lip closeup syringe skincare recovery silicone hyaluronic

evgeny varlamov / Shutterstock.com

“Adding NATRELLE INSPIRA® SoftTouch breast implants to our already robust line of offerings give Allergan the most extensive variety of implants in the industry and provide doctors with a wide range of options, “said Mr. Nicholson.

The new breast implants are approved for reconstruction, which means physicians can use them to replace breast tissue in patients who might have suffered cancer or trauma. Natrelle breast implants can also be used to correct or improve breast reconstruction surgeries.

However, the FDA approval bars women with an active infection anywhere in the body or with existing cancer or precancer from receiving the new implants. Pregnant women or those that are nursing are also advised not to pursue the implants, for obvious reasons. The implants are also approved for women at least 22 years for silicone-filled implants. Saline-filled implants can also be administered to women at least 18 years.

Stock Performance

While the approval is a big win for Allergan Plc (NYSE:AGN), it awaits to be seen if it will have an impact in catapulting the stock higher in the market. For the better part last year the stock was engulfed in a downward trend having tanked to lows of $185 a share before bouncing back as the year ended.

The stock’s immediate resistance currently stands at $220 a share above which the stock could soar to highs of $250 a share. Failure to break above the tight resistance could push the stock lower with immediate support currently at $185 a share.

Allergan Plc (NYSE:AGN) stock was up by $6.18 in Tuesday trading session closing the day at highs of $216.19 a share.

Follow Allergan Plc (NYSE:AGN)
Trade (NYSE:AGN) Now!

Note: This article is written by Adam Russell and originally published at Market Exclusive.